News|Videos|March 11, 2025

CDMO Partnership Reimagined – Novartis Contract Manufacturing

To ensure the development and reliable supply of medicines to patients around the world, pharmaceutical and biotech companies increasingly rely on CDMOs, their capabilities and their output. How do you choose an outsourcing partner that will meet your high expectations, not only in the short term, but throughout the lifetime of your product? Read more here, and watch our video to learn what makes Novartis Contract Manufacturing different.


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.